Cytodyn Inc (CYDY)

[misiu143]

LABZ , and yes , the information from leronlimab phase 2 in LH , is so important for a patients well being , that here one more article...

https://www.news-medical.net/news/20220426/The-impact-of-leronlimab-on-CCR5-surface-cell-levels-during-long-COVID.aspx

But I see so many posts , with questions about this study....

Questions like...

1--" Everyone in a trial has some interest in the study.."
2--"CYDY mislead investors with long covid trial report "
3--" but it is ONLY 55 patients "

So I will try to answer some of these questions..

1-2----This publication is a PEER-REVIEWED publication ....as to point 1 and 2..
.
What that mean..??
from the internet description...

" A peer-reviewed publication is also sometimes referred to as a scholarly publication.The peer-review process subjects an author's scholarly work , research , or ideas to the SCRUTINY OF OTHERS WHO ARE EXPERTS in the same field (peers) and is considered necessary to ensure academic quality "

Peer-review takes many , many months to finish..

These are a very high quality results , no one question them in academia .. ...we may need a bigger trial to confirm the results.if needed , but no questions about these results !!! They are shocking really ...

I believe that Pfizer and Moderna vaccination didn't go with peer-review ... why they didn't is another thing , maybe one day we will know...

3----" But only 55 patients .."

55 patients is not a very low number for our FDA if they want it....

About 3 years ago they approved ibalizumab for combo HIV with every 2 weeks IV infusion , with some serious side effects , and only 42% efficacy , and ONLY 40 patients in phase 3 ..before approval..

So it is not how many patients is in the study , but at what point if ever FDA want to approve it .

During last CC DR Kelly said that to do phase 3 in LH , they looking for a partner...looking at the results from phase 2 , partner should come very soon is my opinion...

B52T38..
And talking about transverse myelitis , I believe leronlimab has a good chance.

GLTA longs.

And ALL imo.